Skip to main content

Rectal cancer surgery - TME, done to audit standard.

Total mesorectal excision for rectal adenocarcinoma - low anterior resection, abdominoperineal resection or transanal TME. Laparoscopic, robotic or open, by a high-volume consultant colorectal cancer surgeon, with MDT staging and neoadjuvant chemoradiotherapy where indicated.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private rectal cancer surgery costs in the UK.

Indicative ranges across our partner colorectal units.

In short

£18,000–£28,000, home in 4–7 nights.

Procedure Indicative range
Laparoscopic low anterior resection (LAR) with TME £18,000–£28,000
Robotic-assisted low anterior resection with TME £24,000–£35,000
Open low anterior resection with TME £16,000–£24,000
Abdominoperineal resection (APR) with permanent colostomy £22,000–£38,000
Transanal TME (TaTME) - hybrid approach £26,000–£45,000
Defunctioning loop ileostomy reversal (later) £6,000–£11,000
Colorectal consultation only £250–£450

Prices vary by hospital, by the consultant, by approach (open, laparoscopic, robotic, TaTME), and by complexity. Robotic and TaTME cases sit at the top of the range. Neoadjuvant and adjuvant oncology are quoted separately.

The problem

The right surgeon, the right MDT, the right sequence.

Rectal cancer is where surgeon volume, TME technique and MDT sequencing matter more than almost any other cancer. We line all three up before you consent.

  • Volume is the outcome

    TME quality tracks with how often a surgeon does rectal work. We only refer to consultants doing rectal cancer weekly.

  • MDT before scalpel

    Every case is discussed by surgeon, oncologist, radiologist and specialist nurse - not decided in a corridor.

  • Neoadjuvant then surgery, in that order

    Locally advanced tumours get chemoradiotherapy first, with a planned interval before TME. Rushing straight to surgery is the wrong sequence.

When it helps

When rectal cancer surgery is the right step.

The situations we see most, plus the red flag that means emergency surgery - not a routine referral.

  • Biopsy-proven rectal adenocarcinoma

    The core indication - a tumour in the rectum confirmed on colonoscopy and biopsy, staged and planned by an MDT before surgery.

  • Upper rectal cancer

    Tumours 10–15 cm from the anal verge - usually a partial mesorectal excision by low anterior resection, sphincters preserved.

  • Mid rectal cancer

    Tumours 5–10 cm from the anal verge - TME by LAR, defunctioning ileostomy standard, sphincters usually preserved.

  • Low rectal cancer

    Tumours within 5 cm of the anal verge - very low LAR, ultralow anastomosis or APR with permanent colostomy depending on tumour and sphincter involvement.

  • Locally advanced disease (T3/T4 or node positive)

    Almost always neoadjuvant chemoradiotherapy first, then TME 8–12 weeks later once the tumour has responded.

  • Early rectal cancer (T1)

    Very early tumours may be suitable for transanal endoscopic microsurgery (TEMS/TAMIS) rather than TME - decided at MDT.

  • Complete clinical response after chemoradiotherapy

    A small number of patients get a complete response - a watch-and-wait pathway may be offered in selected units instead of immediate surgery.

  • Red flag: obstruction, perforation or heavy bleeding

    Sudden inability to pass stool, severe abdominal pain or heavy rectal bleeding is emergency surgery - A&E, not a routine referral.

Procedure options

Approach and extent depend on tumour height and pelvis anatomy.

What each option involves - approach (open, laparoscopic, robotic, transanal) and extent (LAR, APR, TaTME, TEMS) - and when each is right.

  • Low anterior resection (LAR) with TME

    The workhorse for mid and upper rectal cancer. Removes the rectum with its mesorectum, joins colon to remaining rectum or anus, sphincters preserved.

  • Abdominoperineal resection (APR)

    For very low tumours involving the sphincters. Removes rectum, anus and sphincter complex - permanent end colostomy is unavoidable.

  • Transanal TME (TaTME)

    A hybrid approach - abdominal and transanal teams work together. Helps with very low tumours in narrow male pelvises where visibility from above is poor.

  • Laparoscopic approach

    Small-port keyhole surgery. Faster recovery, less pain, comparable oncological outcomes to open in high-volume hands.

  • Robotic-assisted approach

    Da Vinci platform. Better wristed instruments and 3D vision in the narrow male or obese pelvis. Oncological outcomes comparable to laparoscopic; longer theatre time.

  • Open TME

    A laparotomy incision. Reserved for very bulky tumours, difficult adhesions, or where minimally invasive is unsafe.

  • Defunctioning loop ileostomy

    Almost always formed to protect a low anastomosis. Temporary - reversed at a second, smaller operation 3–6 months later once healing is confirmed.

  • Transanal excision (TEMS/TAMIS)

    For selected very early T1 tumours only. Local excision through the anus with no formal TME - a decision made only at MDT after full staging.

Safety and recovery

What to expect afterwards - honestly.

Rectal cancer surgery is major abdominal-pelvic surgery. The realistic risks - anastomotic leak, LAR syndrome, sexual and urinary dysfunction - are worth understanding before you consent.

  • GA and a full colorectal theatre team

    Every rectal cancer resection is under general anaesthetic in a licensed theatre. A colorectal-trained anaesthetist, ERAS pathway, and HDU access if needed.

  • Anastomotic leak is the big early risk

    The join between colon and lower rectum can leak in around 5–15 percent of low anterior resections - which is why a defunctioning loop ileostomy is standard for low joins.

  • Bleeding, infection, DVT and PE

    Wound and pelvic infection under 10 percent. DVT prophylaxis (stockings, heparin, early mobilisation) is routine. Call the same day for fever, calf pain or breathlessness.

  • Injury to nerves, ureters and bladder

    Autonomic pelvic nerves control bladder and sexual function - TME technique aims to preserve them. Injury to ureter or bladder occurs in under 2 percent.

  • Bowel function change (LAR syndrome)

    After low anterior resection, up to half of patients notice frequency, urgency, clustering or incontinence - often improving over 12–18 months, sometimes needing pelvic floor physiotherapy.

  • Permanent stoma after APR

    Abdominoperineal resection means a permanent end colostomy. Stoma nurse support, appliance training and psychological preparation start before surgery, not after.

  • Sexual and urinary dysfunction

    Nerve injury can cause erectile dysfunction, retrograde ejaculation, vaginal dryness or altered bladder emptying. We ask about baseline function so any change is recognised early.

  • Recurrence and long-term surveillance

    Follow-up with clinical review, CEA blood test, CT and colonoscopy over five years. Local recurrence after high-quality TME is around 5 percent.

  • Red flags after surgery

    Fever, rising abdominal pain, no stoma output for 24 hours, heavy bleeding, breathlessness or calf pain need the same-day team or A&E, not a routine call.

Reading your operation note

Your operation note in four parts. Read the last one first.

Whichever approach was used - open, laparoscopic, robotic or TaTME - the note the surgeon sends you keeps to the same shape.

A UK consultant colorectal surgeon reviewing a patient’s operation notes

A quiet reminder

Surgical language is precise and can read coldly - we translate it for you.

If you would like us to talk you through the operation note and the histology before your review, just ask.

  1. 01 Header

    Indication, tumour site and approach

    Why the operation was done, distance of tumour from the anal verge, whether it was open, laparoscopic, robotic or TaTME, and whether a stoma was formed.

  2. 02 Technique

    TME quality and anastomosis

    Whether a complete or near-complete mesorectal envelope was achieved, the type and level of anastomosis, and whether a defunctioning loop ileostomy was fashioned.

  3. 03 Findings

    Histology - margins, nodes, regression

    Circumferential and distal resection margins, lymph node yield and positivity, tumour regression grade after neoadjuvant treatment, lymphovascular invasion.

  4. 04 Impression

    Adjuvant plan and stoma reversal

    Read this first: whether adjuvant chemotherapy is recommended, when stoma reversal is planned, and the surveillance schedule for the next five years.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Rectal cancer surgery is covered when medically indicated. Neoadjuvant and adjuvant oncology are usually authorised separately.

Frequently asked

Everything we get asked about rectal cancer surgery.

Quick answers on TME, stomas, neoadjuvant treatment, approach, cost and NHS comparison.

  • What is total mesorectal excision (TME) and why does it matter?

    TME is the removal of the rectum together with its intact fatty envelope - the mesorectum - which contains the local lymph nodes and drainage. Doing this in the right plane, without breaching the envelope, is the single biggest predictor of low local recurrence and long-term survival in rectal cancer. It is a surgeon-volume story: units and consultants who do rectal cancer work weekly have measurably better TME quality than those who do it occasionally.

  • Will I need a stoma after rectal cancer surgery?

    It depends on the tumour. A low anterior resection preserves the sphincters and usually creates a temporary defunctioning loop ileostomy to protect the low join for 3–6 months. An abdominoperineal resection - for tumours involving the sphincters - means a permanent end colostomy. We discuss which is likely before you consent, and a stoma nurse sees you pre-operatively for siting and teaching.

  • Do I need chemotherapy or radiotherapy before surgery?

    For upper rectal cancers, often no. For most mid and low rectal cancers, especially locally advanced (T3/T4 or node positive) disease, the standard UK pathway is neoadjuvant treatment first - either short-course radiotherapy or long-course chemoradiotherapy - with surgery 8–12 weeks later. The MDT decides based on your MRI staging.

  • Laparoscopic, robotic, TaTME or open - which is right for me?

    Most modern UK units offer laparoscopic or robotic TME as first choice - smaller incisions, faster recovery, comparable oncological outcomes to open. TaTME can help in a very narrow male pelvis with a low tumour. Open surgery is reserved for very bulky tumours, dense adhesions or where minimally invasive is unsafe. The decision is made by your surgeon and MDT - not by patient preference alone.

  • How much does private rectal cancer surgery cost in the UK?

    Roughly £18,000–£28,000 for laparoscopic LAR with TME, £24,000–£35,000 robotic, £22,000–£38,000 for APR, and £26,000–£45,000 for TaTME. Prices vary widely by hospital, surgeon and complexity - the higher end reflects longer theatre time, robotic disposables and prolonged stays. Neoadjuvant chemoradiotherapy and adjuvant chemotherapy are quoted separately.

  • How does this compare to the NHS pathway?

    NHS rectal cancer care is well established and follows the same national guidance - MDT, staging with MRI and CT, neoadjuvant treatment where indicated, TME by specialist colorectal surgeons, and audited outcomes through the National Bowel Cancer Audit. Private care buys shorter waits, choice of consultant and hospital, and single rooms - not different oncological standards. Many patients move between the two pathways.

Related treatments

Looking for something else?